Yes, that is a rock we should have unturned. I'm not concerned at this point, with or without ABT. They are still on the hook financially. Ideally, they would play nice, but that's business. My focus again is approval, which I feel is quite likely, as does DEPO and ABT, apparently. Also, with the FDA giving Orphan Drug Status, it's pretty clear they are on board too.
Market Data 
Markets 
AI
